CL2018001731A1 - Combination therapy. - Google Patents

Combination therapy.

Info

Publication number
CL2018001731A1
CL2018001731A1 CL2018001731A CL2018001731A CL2018001731A1 CL 2018001731 A1 CL2018001731 A1 CL 2018001731A1 CL 2018001731 A CL2018001731 A CL 2018001731A CL 2018001731 A CL2018001731 A CL 2018001731A CL 2018001731 A1 CL2018001731 A1 CL 2018001731A1
Authority
CL
Chile
Prior art keywords
combination therapy
combination
cancer
triplatino
picoplatino
Prior art date
Application number
CL2018001731A
Other languages
Spanish (es)
Inventor
Hugh Griffith
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NuCana plc filed Critical NuCana plc
Priority to CL2018001731A priority Critical patent/CL2018001731A1/en
Publication of CL2018001731A1 publication Critical patent/CL2018001731A1/en

Links

Abstract

COMBINACIÓN QUE COMPRENDE GEMCITABINA-[FENIL-BENZOXI-L-ALANINILO]-FOSFATO Y UN AGENTE ANTI-CÁNCER BASADO EN PLATINO SELECCIONADO DE CISPLATINO, PICOPLATINO, LIPOLATINO Y TRIPLATINO; FORMULACIÓN FARMACÉUTICA QUE LA COMPRENDE; KIT; Y USO DE LA COMBINACIÓN PARA EL TRATAMIENTO DEL CÁNCER.COMBINATION INCLUDING GEMCITABINE- [PHENYL-BENZOXI-L-ALANINYL] -PHOSPHATE AND AN ANTI-CANCER AGENT BASED ON SELECTED CISPLATINO, PICOPLATINO, LIPOLATINO AND TRIPLATINO PLATINUM; PHARMACEUTICAL FORMULATION THAT UNDERSTANDS IT; KIT; AND USE OF THE COMBINATION FOR THE TREATMENT OF CANCER.

CL2018001731A 2018-06-22 2018-06-22 Combination therapy. CL2018001731A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CL2018001731A CL2018001731A1 (en) 2018-06-22 2018-06-22 Combination therapy.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2018001731A CL2018001731A1 (en) 2018-06-22 2018-06-22 Combination therapy.

Publications (1)

Publication Number Publication Date
CL2018001731A1 true CL2018001731A1 (en) 2019-02-01

Family

ID=65588795

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001731A CL2018001731A1 (en) 2018-06-22 2018-06-22 Combination therapy.

Country Status (1)

Country Link
CL (1) CL2018001731A1 (en)

Similar Documents

Publication Publication Date Title
CL2019001874A1 (en) Context-permissive isoform-specific tgfß1 inhibitors and their use.
CO2019013707A2 (en) Aadc polynucleotides for the treatment of parkinson's disease
BR112018003985A2 (en) peptidomimetic macrocycles and their uses
CL2021000149A1 (en) Anti-cd112r compositions and methods
CL2017003436A1 (en) Benzoxacepin oxazolidinone compounds and methods of use
CL2016001609A1 (en) Pharmaceutical compositions comprising azd9291.
BR112019005908A2 (en) use of anti-pd-1 antibody and vegfr inhibitor combination in cancer drug preparation
BR112017023517A2 (en) anti-cd20 antibody for cancer treatment, pharmaceutical composition, method of treating a cancer patient and use of an anti-cd20 antibody
BR112018008601A2 (en) compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
EA201790787A1 (en) REDUCTION OF VISCOSITY OF PHARMACEUTICAL COMPOSITIONS
CL2019001996A1 (en) Therapeutic uses of an insect powder.
CL2017002214A1 (en) Combination formulation of tesofensin and beta blocker
AR114780A1 (en) STABLE ANTI-CD79B IMMUNOCONJUGATE FORMULATIONS
DOP2018000034A (en) COMBINATIONS OF AN OX40 ANTIBODY AND A TLR4 MODULATOR AND USES OF THE SAME
CL2019002427A1 (en) Inhibition of smarca2 for the treatment of cancer.
BR112018002520A2 (en) TLR4 AGONISTS AND COMPOSITIONS OF THE SAME AND ITS USE IN CANCER TREATMENT
ECSP16086247A (en) (S) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
CO2018008445A2 (en) Derivatives of 3- (Carboxyethyl) -8-amino-2-oxo-1,3-diaza-spiro- [4.5] -deca
CL2019002583A1 (en) Dual inhibitors of magl and faah.
WO2019043176A3 (en) Hdac inhibitor in combination with antimetabolite agent for cancer therapy
BR112017014189A2 (en) cancer therapy with a parvovirus combined with bevacizumab
UY37800A (en) IRNA AGENTS FOR THE INHIBITION OF ALFA-ENaC EXPRESSION AND METHODS OF USE
ECSP16086232A (en) (R) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
BR112018014723A2 (en) bacterial ghosts for cancer treatment
BR112017025553A2 (en) vaccine composition, and kit